



**Florida Cancer Specialists & Research Institute Presentations and Publications
at the 2024 ASCO Annual Meeting**

Title	All Authors (Bold = First Author/Presenter)	Session Type	Abstract #
<u>H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC).</u>	Judy Wang, MD Gail Lynn Shaw Wright, MD, FACP, FCCP Fadi Kayali, MD	<u>Rapid Oral Abstract Session</u>	1015
<u>Enfortumab vedotin (EV) in non-squamous and squamous non-small cell lung cancer (NSCLC) cohorts of EV-202.</u>	Todd Gersten, MD	<u>Poster Session</u>	8585
<u>H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC).</u>	Judy Wang, MD	<u>Poster Session</u>	1051
<u>A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.</u>	Manish R. Patel, MD	<u>Poster Session</u>	TPS3166

Tucatinib and trastuzumab for previously treated HER2-mutated metastatic breast cancer (SGNTUC-019): A phase 2 basket study.	Bradley Monk, MD	Poster Session	1105
Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.	Bradley Monk, MD	Poster Session	5607
Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC).	Manish R. Patel, MD	Publication Only	e14587
Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer.	Manish R. Patel, MD	Poster Session	3074
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2- breast cancer (BC).	Manish R. Patel, MD	Poster Session	1056
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.	Vipul Patel, MD	Oral Abstract Session	LBA8500
Efficacy and safety of luveltamab tazevibulin vs investigator's choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.	Bradley Monk, MD	Poster Session	TPS5637

<u>A novel oral microtubule inhibitor utidelone capsule (UTD2): A phase 1 clinical study to assess the tolerability, safety, and efficacy in advanced solid tumors.</u>	Judy Wang, MD Manish R. Patel, MD	<u>Publication Only</u>	e15014
<u>The use of telehealth in a large community oncology practice prior to and during the COVID-19 pandemic.</u>	Kiana Mehrig Lucio N. Gordan, MD	<u>Poster Session</u>	1631
<u>Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors.</u>	Manish R. Patel, MD	<u>Poster Session</u>	2618
<u>Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.</u>	Judy Wang, MD	<u>Poster Session</u>	2582
<u>Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.</u>	Judy Wang, MD Manish Patel, MD	<u>Poster Session</u>	3597
<u>First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.</u>	Cesar Augusto Perez, MD	<u>Poster Session</u>	TPS1128
<u>The predictive value of the MASCC score in patients with febrile neutropenia.</u>	Joel Grossman, MD	<u>Publication Only</u>	e23059
<u>Study of ELU001, a C'Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.</u>	Cesar Augusto Perez, MD	<u>Poster Session</u>	TPS3173
<u>An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1).</u>	Judy Wang, MD	<u>Poster Session</u>	TPS3178
<u>Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors.</u>	Manish R. Patel, MD	<u>Rapid Oral Abstract Session</u>	2521
<u>A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1.</u>	Manish R. Patel, MD	<u>Poster Session</u>	TPS3165

<u>NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.</u>	Maen Hussein, MD	<u>Poster Session</u>	4136
<u>Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.</u>	Cesar Augusto Perez, MD Amir Harandi, MD, MS	<u>Rapid Oral Abstract Session</u>	6014
<u>An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).</u>	Cesar Augusto Perez, MD	<u>Poster Session</u>	TPS3160
<u>Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.</u>	Faithlore Gardner, MD	<u>Poster Session</u>	4046
<u>FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors.</u>	Manish R. Patel, MD	<u>Poster Session</u>	TPS4607
<u>Cracking the code: Can bibliometric attributes predict NIH R01 grant funding outcomes in gastrointestinal oncology? Exploring patterns from a five-year analysis.</u>	Kapisthalam Kumar	<u>Poster Session</u>	9051
<u>Are we bridging the gap? A ten-year probe into NIH grants for early-career and independent investigators in oncology.</u>	Kapisthalam Kumar, MD, FACP	<u>Rapid Oral Abstract Session</u>	9010
<u>Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).</u>	Cesar Augusto Perez, MD	<u>Rapid Oral Abstract Session</u>	8521
<u>Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.</u>	Judy Wang, MD	<u>Poster Session</u>	2588
<u>IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.</u>	Elizabeth Guancial, MD	<u>Poster Session</u>	2599

Emerging Data for Antibody Drug Conjugates in Head and Neck Squamous Cell Carcinoma	Cesar Augusto Perez, MD	Education Session (for CE Credits)	
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.	Judy Wang, MD	Poster Session	8556
Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).	Bradley Monk, MD	Poster Session	1594
Final safety results from ATHENA-MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.	Bradley Monk, MD	Poster Session	5554
A phase 1/2 study of PRO1107, a protein tyrosine kinase 7 (PTK7)-directed antibody drug conjugate (ADC) in patients with advanced solid tumors.	Judy Wang, MD		449374